CliffBio
biologic

Rebinyn

Coagulation Factor IX (Recombinant), GlycoPEGylated

Loss of exclusivityMay 2029projected — 12-year biologic exclusivity estimate
CompanyNovo Nordisk Inc.

Drug detail

Brand nameRebinyn
Active ingredientCoagulation Factor IX (Recombinant), GlycoPEGylated
Strength2000IU
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalMay 2017
Marketing statusRx

More from Novo Nordisk Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Rebinyn patent cliff — loss of exclusivity May 2029 | CliffBio